A PYMNTS Company
Antitrust Chronicle<sup>®</sup> – Killer Acquisitions

Antitrust Chronicle® – Killer Acquisitions

Spring 2020, Volume 2, Number 2

Dear Readers, What is a killer acquisition? The term was first employed in the pharmaceutical sector to describe acquisitions by an incumbent of a competitor that threatened to launch a blockbuster drug that would undermine its own products, with a view to shutting it down. In recent times, the term has broadened to cover other […]

Read More

In this issue

Antitrust Chronicle® – Killer Acquisitions
CPI
May 26, 2020
“Killer Acquisitions,” Big Tech, and Section 2: A Solution in Search of a Problem
Kristen C Limarzi
May 26, 2020
“How Tech Rolls”: Potential Competition and “Reverse” Killer Acquisitions
Cristina Caffarra
May 26, 2020
The No Kill Zone: The Other Side of Pharma Acquisitions
Jacqueline Grise
May 26, 2020
Beyond Killer Acquisitions: Are There More Common Potential Competition Issues in Tech Deals and How Can These Be Assessed?
Oliver Latham
May 26, 2020
Remember Stacker? Another Look at “Killer” Acquisitions in the Digital Economy
Benoit d’Udekem
May 26, 2020
The Jury Is Out: An Assessment of Proposed Reforms to Australia’s Merger Control Regime for Addressing Competitive Harm in the (Digital) Economy
Dave Poddar
May 26, 2020
Assessing “Killer Acquisitions”: An Assets and Capabilities-Based View of the Start-Up
David Pérez de Lamo
May 26, 2020

In case you missed it...

See more Chronicles by year:

Featured News

Eighth Circuit to Hear Appeal of Major Real Estate Antitrust Settlement
Jan 14, 2026 by

Netflix Prepares All-Cash Bid for Warner Bros Discovery Studios and Streaming Assets
Jan 14, 2026 by

Draft Budget Bills Would Slash Trump Administration’s Tech-Funding Requests
Jan 14, 2026 by

Shadow AI Emerges as the New Front Line in GenAI Compliance 
Jan 14, 2026 by

Google Asks Judge to Reject Media Company Claims Over AI Search Overviews
Jan 14, 2026 by